Home › Companies › PCSA
Processa Pharmaceuticals
Market cap $4.8M 2.8M shares (10-Q, Nov 9, 2026) × $1.73 close Nov 17, 2026
Most recent annual filing: 2026-03-15
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- VT-7208 corporate update2H 2026VT-7208 corporate update, 2H 2026, routine
- Preferred Stock Conversion Proposal corporate4Q 2026Preferred Stock Conversion Proposal corporate, 4Q 2026, routine
- Series A Preferred corporate update1Q 2027Series A Preferred corporate update, 1Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (7 active programs)
NGC-Iri
PCS11T
PCS12852
PCS499
VT-7208
VT7208 Technology platforms
Discontinued (1)
- NGC-Cap — Breast Cancer · License agreement with Elion terminated; PCS6422 program returned to Elion; Phase 2 trial in advanced/metastatic breast cancer being closed
Capital (as filed)
- Cash
- $180M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$5.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $180M cash, runway H2 2029 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Processa Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-11 Avoid Processa Pharmaceuticals (PCSA) - Scientific Deep Dive for PCS6422 and Pipeline Products Interesting DPD-inhibition pharmacology is overwhelmed by an existential IP termination lawsuit over the lead asset, a going-concern cash crisis, and management diverting clinical runway into cryptocurrency speculation.
- 2026-05-08 Avoid UPDATE: Processa Pharmaceuticals (PCSA) - The Cash Crash and the Crypto Doubling-Down Q1 10-Q confirms every red flag: cash collapsed from $5.5M to $1.7M in one quarter, the company bought more CHZ crypto, the Elion IP suit grinds on, and outside institutional appetite is effectively zero.
- 2026-07-29 Speculative buy speculative UPDATE: Processa Pharmaceuticals (PCSA) - The Shell Gets a Real Drug A reverse merger with Vidya Therapeutics and a $200M PIPE from Bain/RA Capital/Cormorant transforms the shell into a funded, Phase 1-complete CNS-penetrant BTK inhibitor company with three parallel Phase 2 shots, though legacy holders are diluted to ~0.9% and the PIPE price of $1.22 is the key entry anchor.
- 2026-10-30 Speculative buy speculative UPDATE: Processa Pharmaceuticals (PCSA) - The Adults Take the Wheel FDA cleared the CSU Phase 2 IND on schedule and Sheila Gujrathi was promoted to Executive Chair over capital allocation, addressing the stewardship concern flagged in July, while the PIPE anchor of $1.22 remains the key entry reference.
- 2026-11-14 Speculative buy speculative UPDATE: Processa Pharmaceuticals (PCSA) - The Vote Slips, the Clock Starts The preferred-conversion vote slipped to Q1 2027 against a late-April cash-settlement deadline, Gossamer milestones up to $165.5M were disclosed, and the CHZ crypto position is being unwound at a loss, but the $180M funded balance sheet and BTK thesis remain intact.
- Avoid call · opened Apr 13, 2026 at $2.87 · closed Jul 30, 2026 (flipped bullish) at $2.04 · -28.9% vs XBI +14.7%
- Long call · opened Jul 30, 2026 at $2.04 · -15.2% vs XBI -4.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (21)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Jul 29, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 202610-QQuarterly report→ BD updateThe Q3 10-Q confirms $180M in the bank and VT-7208 on track, but buries two things worth reading: the CHZ crypto position is quietly being wound down at a loss, and a hard April 2027 deadline now hangs over the preferred-stock conversion vote that the entire thesis depends on.
- Nov 5, 2026DEFA14AProxy soliciting material
- Nov 5, 2026DEFA14AProxy soliciting material
- Nov 5, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Nov 4, 2026ReleaseProcessa Pharmaceuticals Announces Key Leadership Appointments
- Nov 4, 20268-KCurrent report: officer / director change, other events · EX-99.1 EXHIBIT 99.1
- Oct 29, 2026ReleaseProcessa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics→ BD updateSummary on the 8-K
- Oct 29, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1→ BD updateThe FDA just cleared the IND for VT-7208's Phase 2 CSU trial — the first hard regulatory milestone since the Vidya reverse merger — and Sheila Gujrathi steps up to Executive Chair while a new oral FcRn antagonist collaboration quietly expands the pipeline.
- Oct 22, 2026DEF 14AProxy statement
- Oct 9, 2026S-3Shelf registration
- Oct 5, 20268-K/ACurrent report (amended): other events · EX-99.3 EXHIBIT 99.3BD extracted 2 program updates from this document → PCSA pipeline
- Sep 1, 2026ReleaseProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Aug 14, 202610-QQuarterly reportBD extracted 1 program update from this document → PCSA pipeline
- Aug 4, 20268-KCurrent report: officer / director change, shareholder vote
- Jul 29, 2026ReleasePROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA
- Jul 29, 20268-KCurrent report: material agreement, agreement terminated, acquisition / disposition · EX-99.1
- Jun 18, 2026DEF 14AProxy statement
- May 7, 202610-QQuarterly report
- Apr 30, 20268-KCurrent report: officer / director change
- Apr 30, 202610-K/AAnnual report (amended)
- Mar 18, 202610-KAnnual report
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)